2 results
Approved WMORecruiting
Among patients under treatment for depression, we will select 140 persons with IMD. In this specific group of patients, we will test whether celecoxib add-on (400 mg/d) is more effective than placebo in the treatment of depression through a 12-week…
Approved WMOCompleted
To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer*s Disease Assessment Scale * cognitive subscale (ADAS-cog); andTo determine the benefit of Dimebon as compared to placebo on the…